(Prote)omics in Next-Gen Drug Development
Collaboration between different omics fields will be key in supporting the next generation of medicines
Mark Rogers | | Opinion
Everybody is different. The stark contrast in individual responses to COVID-19 has gravely highlighted this fact. And we also know responses vary when it comes to medications; what works for one person won’t necessarily work for another. Next-generation medicines promise a more personalized approach to drug development. When therapeutics are customized to an individual’s needs, rather than a broad population, there is a real opportunity to boost efficacy. But where does proteomics come in?
Proteomics plays a crucial role in the discovery of such drugs as it allows the variation in an individual’s response to be characterized at the molecular level. In short, proteomics allows the identification of the structural differences in proteins – a major driver of variation. Subsequently, medicines can be designed to specifically target or exploit these structures.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.